Back

Hepatopulmonary Syndrome

Also known as: HPS

Hepatopulmonary syndrome (HPS) is the triad of liver disease (usually cirrhosis with portal hypertension), arterial hypoxaemia and intrapulmonary vascular dilatation.

Occurs in 5 to 32% of patients with cirrhosis and portal hypertension (also portal vein thrombosis, Budd Chiari).

Pathogenesis: increased pulmonary nitric oxide, endothelin B receptor activity, angiogenesis and monocyte accumulation leading to capillary dilatation (up to 60 µm), ventilation perfusion mismatch, diffusion limitation.

Severity by PaO2: mild 80 mmHg or more, moderate 60 to 80, severe 50 to 60, very severe under 50 mmHg (breathing room air, with A a gradient 15 mmHg or more, or 20 in over 64 years).

Predicts poor survival (median 24 months untreated vs 87 months without HPS); resolves in majority after liver transplantation.

Related

Clinical toolsCalculators

Latest content

Atlas’ Videos

From the newsroom

Atlas is one part of NiajeDoc.

Beyond the reference material, NDN Media Group produces explainers, interviews and health journalism for Kenyan audiences: the conversations that happen around the medicine, not just the protocols.

Explore NiajeDoc

Learn it.
Know it.
Own it.